by Donna Vanderpool, MBA, JD Ms. Vanderpool is Vice President, Risk Management, at PRMS, Inc. Innov Clin Neurosci. 2017;14(5–6):31–32 This ongoing column is dedicated to providing information to our readers
by Geeta Shroff, MD Dr. Shroff is Director of Nutech Mediworld in New Delhi, India. Innov Clin Neurosci. 2017;14(3–4):12–16. Funding: No funding was received for the preparation of this article.
by Chad Gwaltney, PhD; James C Mundt, PhD; John H. Greist, MD; Jean Paty, PhD; and Brian Tiplady, PhD Dr. Gwaltney is with Gwaltney Consulting, Westerly, Rhode Island (with ERT
by Katie T.B. Touma, PharmD, BCPP, BCPS; Allysa M. Zoucha, PharmD, BCPP; and Jonathan R. Scarff, MD Drs. Blissit and Zoucha are with William Jennings Bryan Dorn VA Medical Center,
by Masaru Nakamura, MD, PhD, and Takahiko Nagamine, MD, PhD Dr. Nakamura is with the Department of Psychiatric Internal Medicine, Kosekai-Kusatsu Hospital, in Hiroshima, Japan, and Dr. Nagamine is with
by Jagannadha Avasarala, MD, PhD Dr. Avasarala is with the Department of Internal Medicine, Division of Neurology, Greenville Health System, Neuroscience Associates, in Greenville, South Carolina. Innov Clin Neurosci. 2017;14(3–4):38–40.
by Ann L. McNary, JD Ms. McNary is Senior Risk Manager at PRMS, Inc. in Arlington, Virginia. Innov Clin Neurosci. 2017;14(3–4)41–44. This ongoing column is dedicated to providing information to
by Julieta Dascal, BA; Mark Reid, PhD; Waguih William Ishak, MD, FAPA; Brennan Spiegel, MD, FACG; Jennifer Recacho, MA; Bradley Rosen, MD; and Itai Danovitch, MD, MBA All authors are
by Holly Posner, MD, MS; Rosie Curiel, PsyD; Chris Edgar, PhD; Suzanne Hendrix, PhD; Enchi Liu, PhD; David A. Loewenstein, PhD; Glenn Morrison, MSc, PhD; Leslie Shinobu, PhD; Keith Wesnes,
by Philip D. Harvey, PhD; Stephanie Cosentino, PhD; Rosie Curiel, PhD; Terry E. Goldberg, PhD; Jeffrey Kaye, MD; David Loewenstein, PhD; Daniel Marson, PhD, JD; David Salmon, PhD; Keith Wesnes,
by Zeinab Ebrahimian, MSc; Zeinab Karimi, MSc; Mohammad Javad Khoshnoud, Pharm D, PhD; Mohammad Reza Namavar, PhD; Bahram Daraei, PharmD, PhD; and Moshen Raza Haidari, MD, PhD Drs. Ebrahimian and
by Anoop Narahari, MD; Mariyah Hussain, MD; and Venkatesh Sreeram, MD Drs. Narahari, Hussain, and Sreeram are from the University of Alabama, Department of Psychiatry and Behavioral sciences, Birmingham, Alabama.
by Michael M. Messer, MD, and Irina V. Haller, PhD, MS Dr. Messer is with Behavioral Health Department, Essentia Health, Duluth, MN, and Dr. Haller is with Essentia Institute of
by Charles D. Cash, JD, LLM Mr. Cash is Assistant Vice President of Risk Management at PRMS, Inc., Arlington, Virginia. Innov Clin Neurosci. 2017;14(1–2)60–62. This ongoing column is dedicated to
Innov Clin Neurosci. 2017;14(1–2):11–12. Dear Editor: Sexual dysfunction (SD) after traumatic brain injury (TBI) is an often neglected and underreported issue within the medical field.[1,2] A recent interesting work by
Innov Clin Neuro. 2017;14(1–2):12–13. Dear Editor: Hyperglycemia is more common in patients being treated with an antipsychotic than in the general population.[1] However, hypoglycemia is also a severe complication of
It’s Time for Combination Therapies in Multiple Sclerosis
by Jagannadha Avasarala, MD, PhD Dr. Avasarala is Associate Professor of Neurology, Division of Neurology, Department of Medicine, University of South Carolina School of Medicine, Greenville Health System, Greenville, South
Read More